Biocytogen Completes a New Spherical of Financing Totaling Tens of Thousands and thousands of {Dollars}

BEIJING and BOSTON, June 22, 2021 /PRNewswire/ — Biocytogen, a global biotechnology firm centered on antibody drug analysis and improvement (R&D) utilizing modern genetically engineered animal fashions, at present introduced the profitable completion of a brand new spherical of financing totaling tens of thousands and thousands of {dollars}. The financing was collectively accomplished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed.

Biocytogen Prescription drugs (Beijing) Co., Ltd. was established in 2009. Utilizing its foundational gene modifying expertise, the corporate independently developed mouse platforms for totally human antibody discovery, RenMab® and RenLite®, which have impartial mental property rights. With the implementation of those platforms, Biocytogen has developed from a contract analysis group (CRO) into a global biotechnology firm with experience spanning the whole course of of recent drug R&D, together with antibody drug goal verification, high-throughput single B cell antibody discovery expertise, in vivo drug efficacy analysis utilizing humanized goal mice, and medical improvement.

Genetic engineering of RenMab® and RenLite® mice has enabled the combination of Biocytogen’s technological strengths into a novel large-scale R&D plan for the invention of therapeutic antibodies, an initiative termed the RenMice HiTS Platform. The HiTS Platform signifies the corporate’s dedication to finish high-efficiency antibody discovery and in vivo drug efficacy screening of greater than 1,000 antibody targets within the subsequent few years, specializing in the invention of first-in-class and best-in-class drug targets. Via the identification of antibody leads which have been verified for efficacy in animal fashions, Biocytogen has established co-development partnerships with greater than a dozen biotechnology and pharmaceutical corporations.

Dr. Yuelei Shen, founder and CEO of Biocytogen, stated:
“Within the two months from initiation to completion of this spherical of financing, the corporate has acquired in depth consideration and recognition from prime biomedical funds and long-term funding establishments. New shareholders with excellent reputations are very welcome to hitch the Biocytogen household.

Taking note of the R&D and innovation of the underlying expertise is the cornerstone of our improvement. After greater than ten years of large-scale R&D funding, now we have achieved good ends in the fields of super-large fragment gene modifying expertise, totally human antibody gene mouse improvement expertise, and bispecific antibody improvement expertise. These breakthroughs within the underlying expertise have enabled the corporate to proceed to discover within the fields of monoclonal antibodies, bispecific antibodies, bispecific antibody-ADCs, and nanobodies.

The antibody drug molecules YH003 ([anti-]CD40) and YH001 ([anti-]CTLA-4) independently developed by Biocytogen and its wholly-owned subsidiary, Eucure Biopharma, are in part I medical trials in Australia together with Junshi Biosciences’ PD-1 antibody Toripalimab. Each present glorious security and good drug efficacy. The in vivo experimental knowledge of YH003 and YH001 have been properly verified within the preclinical stage, totally demonstrating the excessive reliability of the biopharmaceutical analysis and improvement technique that makes use of animal efficacy knowledge because the “gold customary” for drug preclinical screening.”

For extra about this fundraising initiative, click on right here.

Partnership & media inquiries:
Jenna Body
[email protected]

SOURCE Biocytogen

Associated Hyperlinks

Related posts

H1 2020 Monetary Outcomes | Enterprise Wire


How the monetary disaster screwed equity, and what to do about it


Arrow Exploration Declares Replace on AIM Itemizing and Financing Course of


Leave a Comment